Rx News Connection: May 2022

  Price  $0.00

  Credits  0.5

Clear

Format
In the medical arena, information changes quickly. What was irrelevant yesterday, may be paramount today. PharmCon’s News Connection series seeks to distill the most impactful news for health professionals from the vast sea of news that confronts us all, then bridge the gap between the immediacy of those critical items and the delay that occurs as that information is incorporated into more focused programming. Our team of skilled editors continually scans the emerging medical news to bring the most relevant pieces to the forefront and deliver them to you in a concise, practical manner. In this session, we investigate timely items, including: New Heart Failure Guidelines, New FDA Approvals, Olaparib Approved for High-Risk Early Breast Cancer, SARS-CoV-2 Omicron Sub-variant BA.2, Brain Changes in COVID-19 Survivors, and Diabetes Risk in COVID-19 Survivors.
$0.00

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Pharmacist

Pharmacy Technician

Nurse

Author

Cara Brock
Managing Editor
Cherie Dillon
Associate Editor
James Chan
PharmD, PhD
Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Pharmacist

Pharmacist

  • Identify recent drug approvals and new indications for FDA-approved or emergency use medications including their role in therapy, administration, side effects, and precautions.
  • Recognize the results of new clinical trials that may have an impact on practitioners and patients.
  • Recall recommendations from clinical guidelines or expert consensus groups affecting patient care.

Pharmacy Technician

Pharmacy Technician

  • Identify recent drug approvals and new indications for FDA-approved or emergency use medications including their role in therapy, administration, side effects, and precautions.
  • Recognize the results of new clinical trials that may have an impact on practitioners and patients.
  • Recall recommendations from clinical guidelines or expert consensus groups affecting patient care.

Nurse

Nurse

  • Identify recent drug approvals and new indications for FDA-approved or emergency use medications including their role in therapy, administration, side effects, and precautions.
  • Recognize the results of new clinical trials that may have an impact on practitioners and patients.
  • Recall recommendations from clinical guidelines or expert consensus groups affecting patient care.


Course Accreditation

  • Activity Type:
    Knowledge
  • Financial Support By:
    PharmCon
  • CE Broker
    901854
  • Universal Activity Number:
    Nurse : 0798-0000-22-108-H01-N
    Pharmacy Technician : 0798-0000-22-108-H01-T
    Pharmacist : 0798-0000-22-108-H01-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.